Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

306 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer.
Argiris A, Li S, Savvides P, Ohr JP, Gilbert J, Levine MA, Chakravarti A, Haigentz M Jr, Saba NF, Ikpeazu CV, Schneider CJ, Pinto HA, Forastiere AA, Burtness B. Argiris A, et al. Among authors: saba nf. J Clin Oncol. 2019 Dec 1;37(34):3266-3274. doi: 10.1200/JCO.19.00555. Epub 2019 Oct 16. J Clin Oncol. 2019. PMID: 31618129 Free PMC article. Clinical Trial.
Targeting angiogenesis in head and neck cancer.
Saba NF, Shin DM, Khuri FR. Saba NF, et al. Curr Cancer Drug Targets. 2007 Nov;7(7):643-9. doi: 10.2174/156800907782418356. Curr Cancer Drug Targets. 2007. PMID: 18045069 Review.
Comparison of quantum dot technology with conventional immunohistochemistry in examining aldehyde dehydrogenase 1A1 as a potential biomarker for lymph node metastasis of head and neck cancer.
Xu J, Müller S, Nannapaneni S, Pan L, Wang Y, Peng X, Wang D, Tighiouart M, Chen Z, Saba NF, Beitler JJ, Shin DM, Chen ZG. Xu J, et al. Among authors: saba nf. Eur J Cancer. 2012 Jul;48(11):1682-91. doi: 10.1016/j.ejca.2011.12.029. Epub 2012 Feb 15. Eur J Cancer. 2012. PMID: 22341992 Free PMC article.
Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer.
Ramalingam SS, Owonikoko TK, Behera M, Subramanian J, Saba NF, Kono SA, Gal AA, Sica G, Harvey RD, Chen Z, Klass CM, Shin DM, Fu H, Sun SY, Govindan R, Khuri FR. Ramalingam SS, et al. Among authors: saba nf. J Thorac Oncol. 2013 Mar;8(3):369-72. doi: 10.1097/JTO.0b013e318282709c. J Thorac Oncol. 2013. PMID: 23407561 Free PMC article. Clinical Trial.
306 results